

DETAILED ACTION

1. Claims 1 and 9-23 are currently pending in the instant application.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with J. Heidi A. Erlacher on February 9, 2012.

In the Claims:

Claim 1: DELETE the following from the end of claim 1 and REPLACE with a period.

provided that the compound is not:

- a) 4-(5-piperidin-4-yl-[1,2,4]oxadiazol-3-yl)pyridine;
- b) 4-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid ^tbutyl ester; or
- c) 4-[5-(4-butylcyclohexyl)-[1,2,4]oxadiazol-3-yl]pyridine.

Claim 15: DELETE "and" in line 23 on page numbered 8 and REPLACE with "or"

DELETE "or" in line 25 on page numbered 8 and REPLACE with "and"

Claim 18: DELETE the phrase "including the compound of proviso c)," from line 2

Claims 19-23: Cancelled

REASONS FOR ALLOWANCE

3. The following is an examiner's statement of reasons for allowance: The instantly claimed compounds and compositions are novel and non-obvious over the prior art. The closest prior art

Art Unit: 1626

is WO 2002/012229, which does not teach the instantly claimed products. This reference does not encompass the scope of the instant application. This reference lacks identical or obvious limitations at positions of the compounds of the instant claims. A person of ordinary skill in the art would not have expected that making structural modifications would retain identical activity as disclosed in the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

4. Claims 1 and 9-18 (renumbered 1-11) are allowed.
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samantha Shterengarts whose telephone number is (571)270-5316. The examiner can normally be reached on Monday thru Thursday 9-6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samantha L. Shterengarts/
Examiner, Art Unit 1626
/Rebecca L Anderson/

Primary Examiner, Art Unit 1626